Last year, the drug industry demanded and won protection from litigation over the use of thimerosal, a preservative in most vaccines believed by some to cause autism.
It favors defendants who are more likely to be able to afford litigation even without anti-SLAPP protection, while leaving the individuals with the least financial capacity without the extra statutory protection.